ReviewDer Pathologe2018
[Lung cancer under stress].
Review in Der Pathologe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutophagy is a cellular mechanism involved in maintaining cellular homeostasis and warranting cellular survival under stress, and may be therapeutically exploited. Autophagy assessment in vitro is well established, but analysis in formalin-fixed and paraffin-embedded (FFPE) tissue is still poorly standardized. Expression analysis of autophagy-associated markers in diagnostic FFPE tissue aids in translating in vitro findings to the clinic and may contribute to a future quest for predictive markers. MATERIAL AND
methodsWe have established a reliable visualization of autophagy-related proteins in FFPE tissue by immunohistochemistry, using lung cancer cell lines with functionally modified autophagy states and marker-depletion, respectively, and evaluated the prognostic impact of autophagy-related markers in lung cancer patients.
resultsDot-like staining was observed for LC3 and p62, representing the degrading autophagic vesicles. Stainings correlated significantly with quantitative protein expression assessed by western blot in cell lines and FFPE tumor tissue. In stage I/II non-small cell lung cancer cases and a large cohort of pulmonary squamous cell carcinomas, dot-like LC3 and p62 staining lacked clear prognostic value, but p62 expression was an independent prognostic factor for shorter survival in both cohorts and using internal validation models.
conclusionsValid visualization of autophagy-related markers in FFPE tissue is feasible. We could not demonstrate a clear prognostic role of autophagy status as deducted from LC3-p62 co-expression. The autophagy independent role of p62 in lung cancer warrants further investigation, as well as crosstalk with other stress factors or the role of autophagy induction during or after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.